When The New York Times reported a few days ago that the Trump administration has picked five COVID-19 vaccines to receive substantial financial support of the U.S. government, there was one company mentioned first. You guessed it... Moderna.
Is Moderna really the de facto leader in the COVID-19 vaccine race? It's complicated.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,